Mirum Pharmaceuticals, Inc. $MIRM Stake Lessened by SG Americas Securities LLC

SG Americas Securities LLC cut its stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 74.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,715 shares of the company’s stock after selling 13,995 shares during the period. SG Americas Securities LLC’s holdings in Mirum Pharmaceuticals were worth $436,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in MIRM. SBI Okasan Asset Management Co.Ltd. acquired a new stake in shares of Mirum Pharmaceuticals in the 4th quarter valued at about $1,283,000. Nan Fung Trinity HK Ltd. lifted its position in shares of Mirum Pharmaceuticals by 45.6% during the fourth quarter. Nan Fung Trinity HK Ltd. now owns 227,479 shares of the company’s stock worth $17,969,000 after purchasing an additional 71,214 shares during the last quarter. Hillsdale Investment Management Inc. acquired a new position in Mirum Pharmaceuticals in the fourth quarter worth about $3,762,000. Tudor Investment Corp ET AL bought a new stake in Mirum Pharmaceuticals in the third quarter valued at about $2,027,000. Finally, Thrivent Financial for Lutherans bought a new stake in Mirum Pharmaceuticals in the fourth quarter valued at about $3,306,000.

Insider Activity at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, CFO Eric Bjerkholt sold 5,000 shares of Mirum Pharmaceuticals stock in a transaction on Monday, July 6th. The stock was sold at an average price of $122.25, for a total transaction of $611,250.00. Following the sale, the chief financial officer owned 42,181 shares of the company’s stock, valued at $5,156,627.25. The trade was a 10.60% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher Peetz sold 20,000 shares of the stock in a transaction on Monday, July 6th. The stock was sold at an average price of $122.27, for a total value of $2,445,400.00. Following the completion of the transaction, the chief executive officer directly owned 194,309 shares of the company’s stock, valued at approximately $23,758,161.43. The trade was a 9.33% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 65,315 shares of company stock worth $6,991,928 in the last three months. 8.32% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

MIRM has been the topic of a number of research analyst reports. Weiss Ratings downgraded Mirum Pharmaceuticals from a “sell (d)” rating to a “sell (d-)” rating in a report on Tuesday, June 23rd. Citizens Jmp boosted their price target on Mirum Pharmaceuticals from $140.00 to $146.00 and gave the company a “market outperform” rating in a report on Monday, June 15th. Raymond James Financial reissued a “strong-buy” rating and set a $165.00 price target on shares of Mirum Pharmaceuticals in a research report on Thursday, May 7th. JPMorgan Chase & Co. lifted their price objective on shares of Mirum Pharmaceuticals from $115.00 to $125.00 and gave the stock an “overweight” rating in a report on Thursday, July 2nd. Finally, CLSA set a $146.00 target price on shares of Mirum Pharmaceuticals in a research note on Monday, June 15th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Mirum Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $143.40.

Mirum Pharmaceuticals Price Performance

Shares of MIRM opened at $128.57 on Thursday. Mirum Pharmaceuticals, Inc. has a 12 month low of $50.25 and a 12 month high of $129.00. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.09 and a quick ratio of 1.99. The stock has a fifty day moving average price of $105.26 and a 200 day moving average price of $97.20. The company has a market cap of $7.84 billion, a P/E ratio of -9.45 and a beta of 0.48.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its earnings results on Wednesday, May 6th. The company reported ($13.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($12.68). The company had revenue of $159.88 million during the quarter, compared to the consensus estimate of $148.21 million. Mirum Pharmaceuticals had a negative net margin of 140.24% and a negative return on equity of 11.28%. The business’s quarterly revenue was up 43.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.30) earnings per share. On average, research analysts forecast that Mirum Pharmaceuticals, Inc. will post -2.01 earnings per share for the current year.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.